Comparative Pharmacology
Head-to-head clinical analysis: DORIDEN versus PLACIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIDEN versus PLACIDYL.
DORIDEN vs PLACIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barbiturate-like sedative-hypnotic; acts on GABA-A receptors to enhance inhibitory neurotransmission, causing CNS depression.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
500 mg orally at bedtime, maximum 1 g per day; for sedation, 250 mg 3 times daily after meals.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
None Documented
None Documented
Terminal elimination half-life is 4-10 hours in healthy adults; prolonged in elderly and patients with hepatic impairment, increasing to 12-20 hours.
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Renal (accounting for approximately 80% of elimination, primarily as glucuronide conjugates and unchanged drug); biliary/fecal (minor, about 10%).
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic